Puma Biotechnology Ownership
| PBYI Stock | USD 5.86 0.08 1.35% |
Shares in Circulation | First Issued 2007-09-30 | Previous Quarter 50.1 M | Current Value 50.9 M | Avarage Shares Outstanding 30 M | Quarterly Volatility 16 M |
Puma Stock Ownership Analysis
About 15.0% of the company outstanding shares are owned by corporate insiders. The book value of Puma Biotechnology was at this time reported as 2.29. The company has Price/Earnings To Growth (PEG) ratio of 0.03. Puma Biotechnology had not issued any dividends in recent years. Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company was founded in 2010 and is headquartered in Los Angeles, California. Puma Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 196 people. To find out more about Puma Biotechnology contact Alan Auerbach at 424 248 6500 or learn more at https://www.pumabiotechnology.com.Besides selling stocks to institutional investors, Puma Biotechnology also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Puma Biotechnology's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Puma Biotechnology's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Puma Biotechnology Quarterly Liabilities And Stockholders Equity |
|
Puma Biotechnology Insider Trades History
About 15.0% of Puma Biotechnology are currently held by insiders. Unlike Puma Biotechnology's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Puma Biotechnology's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Puma Biotechnology's insider trades
Puma Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Puma Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Puma Biotechnology backward and forwards among themselves. Puma Biotechnology's institutional investor refers to the entity that pools money to purchase Puma Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Lsv Asset Management | 2025-06-30 | 535.7 K | Citadel Advisors Llc | 2025-06-30 | 507.8 K | Globeflex Capital, L.p. | 2025-06-30 | 452.6 K | Arrowstreet Capital Limited Partnership | 2025-06-30 | 451.6 K | Los Angeles Capital Management Llc | 2025-06-30 | 445.5 K | O'shaughnessy Asset Management Llc | 2025-06-30 | 437.7 K | Sei Investments Co | 2025-06-30 | 347.2 K | Bank Of New York Mellon Corp | 2025-06-30 | 344.1 K | Millennium Management Llc | 2025-06-30 | 334.6 K | Blackrock Inc | 2025-06-30 | 3.8 M | Vanguard Group Inc | 2025-06-30 | 3.7 M |
Puma Biotechnology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Puma Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Puma Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Puma Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Puma Biotechnology Outstanding Bonds
Puma Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Puma Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Puma bonds can be classified according to their maturity, which is the date when Puma Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| PulteGroup 6 percent Corp BondUS745867AT82 | View | |
| PulteGroup 55 percent Corp BondUS745867AW12 | View | |
| PulteGroup 5 percent Corp BondUS745867AX94 | View | |
| PulteGroup 7875 percent Corp BondUS745867AM30 | View | |
| PulteGroup 6375 percent Corp BondUS745867AP60 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Puma Biotechnology Corporate Filings
F4 | 13th of November 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 6th of November 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 7th of August 2025 Other Reports | ViewVerify | |
| 28th of April 2025 Other Reports | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.74 | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.